NASDAQ:ARDXArdelyx Stock Price, Forecast & News

$7.26

-0.07 (-0.95 %)

(As of 06/1/2020 12:32 PM ET)

Add

Compare

Today's Range

$7.19

Now: $7.26▼

$7.50

50-Day Range

$5.71

MA: $7.13▼

$8.07

52-Week Range

$2.10

Now: $7.26▼

$8.81

Volume7,904 shs

Average Volume668,635 shs

Market Capitalization$645.63 million

P/E RatioN/A

Dividend YieldN/A

Beta1.9

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Ardelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $12.00, Ardelyx has a potential upside of 63.9% from its current price of $7.32.
Amount of Analyst Coverage
Ardelyx has received no research coverage in the past 90 days.

2.7 Community Rank

Outperform Votes
Ardelyx has received 473 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Ardelyx has received 418 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Ardelyx has received 53.09% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote “Outperform” if you believe ARDX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Ardelyx does not currently pay a dividend.
Dividend Growth
Ardelyx does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $392,452.00 in company stock.
Percentage Held by Insiders
Only 15.31% of the stock of Ardelyx is held by insiders.
Percentage Held by Institutions
86.08% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Ardelyx are expected to grow in the coming year, from ($1.05) to ($0.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ardelyx is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ardelyx is -5.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ardelyx has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.57 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ARDX

Previous Symbol

CUSIPN/A

CIK1437402

Webwww.ardelyx.com

Phone510-745-1700

Debt

Debt-to-Equity Ratio0.26

Current Ratio9.76

Quick Ratio9.76

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.28 million

Price / Sales122.28

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.10 per share

Price / Book3.46

Profitability

EPS (Most Recent Fiscal Year)($1.47)

Net Income$-94,940,000.00

Net Margins-1,403.90%

Return on Equity-77.23%

Return on Assets-48.46%

Miscellaneous

Employees88

Outstanding Shares88,930,000

Market Cap$645.63 million

Next Earnings Date8/14/2020 (Estimated)

OptionableOptionable

Receive ARDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ARDX and its competitors with MarketBeat's FREE daily newsletter.

Ardelyx (NASDAQ:ARDX) Frequently Asked Questions

How has Ardelyx's stock been impacted by COVID-19 (Coronavirus)?

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ARDX shares have increased by 22.4% and is now trading at $7.32. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ardelyx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ardelyx.

When is Ardelyx's next earnings date?

Ardelyx is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Ardelyx.

How were Ardelyx's earnings last quarter?

Ardelyx Inc (NASDAQ:ARDX) issued its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.00. The biopharmaceutical company had revenue of $1.21 million for the quarter, compared to analysts' expectations of $0.90 million. Ardelyx had a negative return on equity of 77.23% and a negative net margin of 1,403.90%. View Ardelyx's earnings history.

What price target have analysts set for ARDX?

5 equities research analysts have issued 1 year price objectives for Ardelyx's stock. Their forecasts range from $9.00 to $15.00. On average, they expect Ardelyx's stock price to reach $12.00 in the next year. This suggests a possible upside of 63.9% from the stock's current price. View analysts' price targets for Ardelyx.

Has Ardelyx been receiving favorable news coverage?

Press coverage about ARDX stock has trended somewhat positive on Monday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ardelyx earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutArdelyx.

Who are some of Ardelyx's key competitors?

Some companies that are related to Ardelyx include Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Turning Point Therapeutics (TPTX), Insmed (INSM), Karuna Therapeutics (KRTX), Intercept Pharmaceuticals (ICPT), Ra Pharmaceuticals (RARX), Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), TG Therapeutics (TGTX), IGM Biosciences (IGMS), Eidos Therapeutics (EIDX), Passage Bio (ZNTL) and Pacira Biosciences (PCRX). View all competitors.

What other stocks do shareholders of Ardelyx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Gilead Sciences (GILD), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP), BioCryst Pharmaceuticals (BCRX), ImmunoGen (IMGN), SCYNEXIS (SCYX), AbbVie (ABBV), NVIDIA (NVDA) and Rigel Pharmaceuticals (RIGL).

Who are Ardelyx's key executives?

Ardelyx's management team includes the following people:

Mr. Michael G. Raab, Pres, CEO & Director (Age 55, Pay $988k)
Ms. Elizabeth A. Grammer, Chief Legal & Admin. Officer and Sec. (Age 56, Pay $596k)
Mr. David Rosenbaum, Chief Devel. Officer (Age 59, Pay $617.25k)
Mr. Keith Santorelli, Acting Principal Financial & Accounting Officer (Age 46)
Mr. Jeffrey W. Jacobs, Chief Scientific Officer (Age 57)

What is Ardelyx's stock symbol?

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Who are Ardelyx's major shareholders?

Ardelyx's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (7.22%), BlackRock Inc. (7.89%), Redmile Group LLC (4.39%), Ikarian Capital LLC (1.64%), State Street Corp (1.30%) and Geode Capital Management LLC (1.13%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann, Michael Raab and Scott D Sandell. View institutional ownership trends for Ardelyx.

Which major investors are selling Ardelyx stock?

ARDX stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Squarepoint Ops LLC, Redmile Group LLC, Invesco Ltd., Wexford Capital LP, UBS Group AG, DAFNA Capital Management LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann, and Michael Raab. View insider buying and selling activity for Ardelyx.

Which major investors are buying Ardelyx stock?

ARDX stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., BlackRock Inc., Ikarian Capital LLC, Morgan Stanley, Morgan Stanley, State Street Corp, Bailard Inc., and AQR Capital Management LLC. View insider buying and selling activity for Ardelyx.

How do I buy shares of Ardelyx?

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ardelyx's stock price today?

One share of ARDX stock can currently be purchased for approximately $7.32.

How big of a company is Ardelyx?

Ardelyx has a market capitalization of $650.97 million and generates $5.28 million in revenue each year. The biopharmaceutical company earns $-94,940,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis. Ardelyx employs 88 workers across the globe.

What is Ardelyx's official website?

The official website for Ardelyx is www.ardelyx.com.

How can I contact Ardelyx?

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff